首页 > 最新文献

JNCI Cancer Spectrum最新文献

英文 中文
QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials. CDK4/6 抑制剂的 QTc 延长:随机对照试验的系统回顾和荟萃分析。
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-09-02 DOI: 10.1093/jncics/pkae078
Bruno Murad, Pedro C A Reis, Alice Deberaldini Marinho, Ana Carolina Marin Comini, Débora Pinheiro Xavier, Beatriz Mella Soares Pessoa, Farah Raheem, Brenda Ernst, Lida A Mina, Felipe Batalini

Background: Cyclin-dependent kinases (CDK) 4/6 inhibitors have significantly improved outcomes for patients with ER+/HER2- breast cancer. Nevertheless, they differ from each other in terms of chemical, biological, and pharmacological features, as well as toxicity profiles. We aim to determine whether QTc prolongation is caused by CDK4/6i in general or if it is associated with ribociclib only.

Methods: We systematically searched PubMed, Embase, and Cochrane Library for randomized controlled trials (RCTs) comparing the prevalence of QTc prolongation as an adverse event in HR+ breast cancer patients treated with CDK4/6i vs those without CDK4/6i. We pooled relative risk (RR) and mean difference (MD) with 95% confidence interval (CI) for the binary endpoint of QT prolongation.

Results: We included 14 RCTs comprising 16 196 patients, of whom 8576 underwent therapy with CDK4/6i. An increased risk of QTc prolongation was associated with the use of CDK4/6i (RR = 2.35, 95% CI = 1.67 to 3.29, P < .001; I2 = 44%). Subgroup analyses revealed a significant increase in the QTc interval for the ribociclib and palbociclib cohorts. The ribociclib subgroup showed a relative risk of 3.12 (95% CI = 2.09 to 4.65, P < .001; I2 = 12%), whereas the palbociclib subgroup had a relative risk of 1.51 (95% CI = 1.05 to 2.15, P = .025; I2 = 0%).

Conclusion: Palbociclib was associated with QTc prolongation; however, the relative risk for any grade QTc was quantitively twice with ribociclib. Furthermore, grade 3 QTc prolongations were observed exclusively with ribociclib. These results are important for guiding clinical decision-making and provide reassurance regarding the overall safety profile of this drug class.

背景:细胞周期蛋白依赖性激酶(CDK)4/6抑制剂大大改善了ER+/HER2-乳腺癌患者的预后。然而,它们在化学、生物和药理特征以及毒性方面各不相同。我们旨在确定QTc延长是由CDK4/6i引起的,还是仅与ribociclib有关:我们系统检索了PubMed、Embase和Cochrane图书馆的随机对照试验(RCTs),比较了接受CDK4/6i治疗与未接受CDK4/6i治疗的HR+乳腺癌患者中QTc延长作为不良事件的发生率。我们汇总了QT延长二元终点的风险比(RR)和平均差(MD)及95%置信区间(CI):我们纳入了 14 项 RCT,共 16196 例患者,其中 8576 例接受了 CDK4/6i 治疗。使用 CDK4/6i 会增加 QTc 延长的风险(RR 2.35;95% CI 1.67-3.29;P 结论:Palbociclib 与 QTc 延长有关:Palbociclib与QTc延长有关,但任何等级QTc的RR是ribociclib的两倍。此外,3级QTc延长仅出现在ribociclib上。这些结果对指导临床决策非常重要,并为该类药物的整体安全性提供了保证。
{"title":"QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials.","authors":"Bruno Murad, Pedro C A Reis, Alice Deberaldini Marinho, Ana Carolina Marin Comini, Débora Pinheiro Xavier, Beatriz Mella Soares Pessoa, Farah Raheem, Brenda Ernst, Lida A Mina, Felipe Batalini","doi":"10.1093/jncics/pkae078","DOIUrl":"10.1093/jncics/pkae078","url":null,"abstract":"<p><strong>Background: </strong>Cyclin-dependent kinases (CDK) 4/6 inhibitors have significantly improved outcomes for patients with ER+/HER2- breast cancer. Nevertheless, they differ from each other in terms of chemical, biological, and pharmacological features, as well as toxicity profiles. We aim to determine whether QTc prolongation is caused by CDK4/6i in general or if it is associated with ribociclib only.</p><p><strong>Methods: </strong>We systematically searched PubMed, Embase, and Cochrane Library for randomized controlled trials (RCTs) comparing the prevalence of QTc prolongation as an adverse event in HR+ breast cancer patients treated with CDK4/6i vs those without CDK4/6i. We pooled relative risk (RR) and mean difference (MD) with 95% confidence interval (CI) for the binary endpoint of QT prolongation.</p><p><strong>Results: </strong>We included 14 RCTs comprising 16 196 patients, of whom 8576 underwent therapy with CDK4/6i. An increased risk of QTc prolongation was associated with the use of CDK4/6i (RR = 2.35, 95% CI = 1.67 to 3.29, P < .001; I2 = 44%). Subgroup analyses revealed a significant increase in the QTc interval for the ribociclib and palbociclib cohorts. The ribociclib subgroup showed a relative risk of 3.12 (95% CI = 2.09 to 4.65, P < .001; I2 = 12%), whereas the palbociclib subgroup had a relative risk of 1.51 (95% CI = 1.05 to 2.15, P = .025; I2 = 0%).</p><p><strong>Conclusion: </strong>Palbociclib was associated with QTc prolongation; however, the relative risk for any grade QTc was quantitively twice with ribociclib. Furthermore, grade 3 QTc prolongations were observed exclusively with ribociclib. These results are important for guiding clinical decision-making and provide reassurance regarding the overall safety profile of this drug class.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Financial distress and medical financial hardship among young adult survivors of blood cancer. 血癌年轻成年幸存者的经济压力和医疗经济困难。
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-09-02 DOI: 10.1093/jncics/pkae071
Susan K Parsons, Rachel Murphy-Banks, Angie Mae Rodday, Michael E Roth, Kimberly Miller, Nadine Linendoll, Randall Chan, Howland E Crosswell, Qingyan Xiang, David R Freyer

Background: The long-term financial impact of cancer care has not been adequately addressed in young adults. As part of a remote intervention study, we describe medical financial distress and hardship among young adult survivors of blood cancer at study entry.

Methods: Young adults were recruited from 6 US hospitals. Using a Research Electronic Data Capture link, young adults confirmed their eligibility-namely, currently 18 to 39 years of age, blood cancer diagnosis 3 or more years ago, off active treatment, and not on parent's insurance. Following consent, the baseline assessment was sent. The primary outcome measure, the Personal Financial Wellness Scale, measured financial distress (scored as severe, 1-2; high, 3-4; average, 5-6; and low to no, 7-10). Medical financial hardship encompassed material hardship, psychological impact, and coping behaviors. Descriptive summary statistics and linear regression were used.

Results: Among the 126 participants, 54.5% came from minority racial or ethnic groups. Median time since diagnosis was 10 years (interquartile range = 6-16 years), with 56% having received a diagnosis when they were between 18 and 39 years of age. The overall mean (standard deviation) Personal Financial Wellness Scale score was 5.1 (2.4), but 49% reported severe or high distress. In multivariable analysis, female sex, Hispanic ethnicity, and lower income were strongly associated with worse Personal Financial Wellness Scale scores. Among participants with severe financial distress (n = 26), 72% reported 2 or more household material hardships, had worse scores across all psychological domains, and altered survivorship care because of cost (68%).

Conclusions: Nearly half of long-term young adult cancer survivors reported severe or high levels of financial distress. Individuals with severe or high distress also reported more medical financial hardship than other participants. This finding highlights the need for ongoing financial intervention in this vulnerable population.

Clinicaltrials.gov: NCT05620979.

背景:癌症治疗的长期经济影响尚未在年轻人(YAs)中得到充分关注。作为远程干预研究的一部分,我们描述了血癌青年幸存者在研究开始时的医疗财务困境和困难:方法:从美国六家医院招募青年癌症幸存者。通过 REDCap™ 链接,青少年确认了研究资格:目前年龄在 18-39 岁之间,确诊血癌时间≥3 年,已停止积极治疗,且未参加父母的保险。在征得同意后,我们发送了基线评估。个人财务健康(PFW)量表是衡量财务困境的主要结果(评分:1-2 分严重,3-4 分高,5-6 分一般,7-10 分低到无)。医疗经济困难包括物质困难、心理影响和应对行为。研究采用了描述性简要统计和线性回归方法:126名参与者中,54.5%为少数种族/族裔。确诊时间中位数为 10 年(IQR,6-16),56% 的患者确诊年龄在 18-39 岁之间。总体平均 PFW 得分为 5.1(SD = 2.4),但 49% 的人表示有严重或高度的痛苦。在多变量分析中,女性、西班牙裔和较低的收入与较差的 PFW 分数显著相关。在有严重经济困难的参与者中(n = 26),72%的人报告了≥2种家庭物质困难,所有心理领域的得分都较差,并且由于费用问题而改变了幸存者护理(68%):讨论:近一半的长期亚健康幸存者报告了严重或高度的经济窘迫。与其他参与者相比,处于严重或高度困境中的亚裔还报告了更多的医疗经济困难。这凸显了对这一弱势群体进行持续财务干预的必要性:NCT05620979。
{"title":"Financial distress and medical financial hardship among young adult survivors of blood cancer.","authors":"Susan K Parsons, Rachel Murphy-Banks, Angie Mae Rodday, Michael E Roth, Kimberly Miller, Nadine Linendoll, Randall Chan, Howland E Crosswell, Qingyan Xiang, David R Freyer","doi":"10.1093/jncics/pkae071","DOIUrl":"10.1093/jncics/pkae071","url":null,"abstract":"<p><strong>Background: </strong>The long-term financial impact of cancer care has not been adequately addressed in young adults. As part of a remote intervention study, we describe medical financial distress and hardship among young adult survivors of blood cancer at study entry.</p><p><strong>Methods: </strong>Young adults were recruited from 6 US hospitals. Using a Research Electronic Data Capture link, young adults confirmed their eligibility-namely, currently 18 to 39 years of age, blood cancer diagnosis 3 or more years ago, off active treatment, and not on parent's insurance. Following consent, the baseline assessment was sent. The primary outcome measure, the Personal Financial Wellness Scale, measured financial distress (scored as severe, 1-2; high, 3-4; average, 5-6; and low to no, 7-10). Medical financial hardship encompassed material hardship, psychological impact, and coping behaviors. Descriptive summary statistics and linear regression were used.</p><p><strong>Results: </strong>Among the 126 participants, 54.5% came from minority racial or ethnic groups. Median time since diagnosis was 10 years (interquartile range = 6-16 years), with 56% having received a diagnosis when they were between 18 and 39 years of age. The overall mean (standard deviation) Personal Financial Wellness Scale score was 5.1 (2.4), but 49% reported severe or high distress. In multivariable analysis, female sex, Hispanic ethnicity, and lower income were strongly associated with worse Personal Financial Wellness Scale scores. Among participants with severe financial distress (n = 26), 72% reported 2 or more household material hardships, had worse scores across all psychological domains, and altered survivorship care because of cost (68%).</p><p><strong>Conclusions: </strong>Nearly half of long-term young adult cancer survivors reported severe or high levels of financial distress. Individuals with severe or high distress also reported more medical financial hardship than other participants. This finding highlights the need for ongoing financial intervention in this vulnerable population.</p><p><strong>Clinicaltrials.gov: </strong>NCT05620979.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11401610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141995749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of anxiety disorders in men with prostate cancer: a national cohort study. 前列腺癌男性患者罹患焦虑症的风险:一项全国队列研究
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-09-02 DOI: 10.1093/jncics/pkae087
Casey Crump, Pär Stattin, James D Brooks, Jan Sundquist, Kristina Sundquist, Weiva Sieh

Background: Men with prostate cancer (PC) may experience significant psychosocial distress from physical symptoms, treatment side effects, or fear of recurrence. However, little is known about the long-term risk of anxiety disorders in men with PC.

Methods: A national cohort study was conducted of 180 189 men diagnosed with PC during 1998-2017 and 1 801 890 age-matched population-based control men in Sweden. Anxiety disorders were ascertained from nationwide outpatient and inpatient records through 2018. Cox regression was used to estimate hazard ratios (HRs) while adjusting for sociodemographic factors and prior psychiatric disorders. Subanalyses explored differences by PC treatment during 2005-2017.

Results: In 7.8 million person-years of follow-up, 94 387 (5%) men were diagnosed with anxiety disorders. Men with high-risk PC had a nearly 2-fold higher risk of anxiety disorders than control men without PC (adjusted HR = 1.96, 95% CI = 1.87 to 2.05). This risk was highest in the first 3 months after PC diagnosis (adjusted HR = 2.99, 95% CI = 2.49 to 3.59) but remained significantly elevated 10 or more years later (adjusted HR = 1.53, 95% CI = 1.35 to 1.74). Those treated only with androgen deprivation therapy (ADT) had the highest risk of anxiety disorders (adjusted HR = 2.08, 95% CI = 1.93 to 2.25). Men with low- or intermediate-risk PC had a modestly increased risk (adjusted HR = 1.39, 95% CI = 1.34 to 1.44).

Conclusions: In this large national cohort, men with PC had substantially increased risk of anxiety disorders, especially those with high-risk PC and treated only with ADT. Men with PC need close monitoring for timely detection and treatment of anxiety symptoms, particularly shortly after PC diagnosis.

背景:患有前列腺癌(PC)的男性可能会因身体症状、治疗副作用或对复发的恐惧而遭受严重的心理社会困扰。然而,人们对患有前列腺癌的男性患焦虑症的长期风险知之甚少:瑞典对 1998-2017 年间确诊为 PC 患者的 180,189 名男性和 1,801,890 名年龄匹配的对照组男性进行了全国性队列研究。焦虑症是从截至 2018 年的全国门诊和住院病人记录中确定的。在调整社会人口因素和既往精神障碍的同时,采用 Cox 回归估算危险比 (HR)。子分析探讨了 2005-2017 年间 PC 治疗的差异:在 780 万人年的随访中,有 94,387 名男性(5%)被诊断患有焦虑症。患高风险 PC 的男性罹患焦虑症的风险比未患 PC 的对照男性高出近 2 倍(调整后 HR 为 1.96;95% CI 为 1.87-2.05)。这种风险在确诊 PC 后的头 3 个月最高(调整后 HR,2.99;95% CI,2.49-3.59),但≥10 年后仍然显著升高(调整后 HR,1.53;95% CI,1.35-1.74)。仅接受雄激素剥夺疗法(ADT)治疗的男性患焦虑症的风险最高(调整后HR为2.08;95% CI为1.93-2.25)。患有低危或中危PC的男性患焦虑症的风险略有增加(调整后HR为1.39;95% CI为1.34-1.44):在这一大型全国性队列中,患有 PC 的男性患焦虑症的风险大幅增加,尤其是那些患有高风险 PC 且仅接受 ADT 治疗的男性。男性 PC 患者需要密切监测,及时发现并治疗焦虑症状,尤其是在确诊 PC 后不久。
{"title":"Risk of anxiety disorders in men with prostate cancer: a national cohort study.","authors":"Casey Crump, Pär Stattin, James D Brooks, Jan Sundquist, Kristina Sundquist, Weiva Sieh","doi":"10.1093/jncics/pkae087","DOIUrl":"10.1093/jncics/pkae087","url":null,"abstract":"<p><strong>Background: </strong>Men with prostate cancer (PC) may experience significant psychosocial distress from physical symptoms, treatment side effects, or fear of recurrence. However, little is known about the long-term risk of anxiety disorders in men with PC.</p><p><strong>Methods: </strong>A national cohort study was conducted of 180 189 men diagnosed with PC during 1998-2017 and 1 801 890 age-matched population-based control men in Sweden. Anxiety disorders were ascertained from nationwide outpatient and inpatient records through 2018. Cox regression was used to estimate hazard ratios (HRs) while adjusting for sociodemographic factors and prior psychiatric disorders. Subanalyses explored differences by PC treatment during 2005-2017.</p><p><strong>Results: </strong>In 7.8 million person-years of follow-up, 94 387 (5%) men were diagnosed with anxiety disorders. Men with high-risk PC had a nearly 2-fold higher risk of anxiety disorders than control men without PC (adjusted HR = 1.96, 95% CI = 1.87 to 2.05). This risk was highest in the first 3 months after PC diagnosis (adjusted HR = 2.99, 95% CI = 2.49 to 3.59) but remained significantly elevated 10 or more years later (adjusted HR = 1.53, 95% CI = 1.35 to 1.74). Those treated only with androgen deprivation therapy (ADT) had the highest risk of anxiety disorders (adjusted HR = 2.08, 95% CI = 1.93 to 2.25). Men with low- or intermediate-risk PC had a modestly increased risk (adjusted HR = 1.39, 95% CI = 1.34 to 1.44).</p><p><strong>Conclusions: </strong>In this large national cohort, men with PC had substantially increased risk of anxiety disorders, especially those with high-risk PC and treated only with ADT. Men with PC need close monitoring for timely detection and treatment of anxiety symptoms, particularly shortly after PC diagnosis.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Germline reflex BRCA1/2 testing following tumor-only comprehensive genomic profiling: why, when, and how. 肿瘤综合基因组图谱检测后的生殖系反射性 BRCA1/2 检测:原因、时间和方法。
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-09-02 DOI: 10.1093/jncics/pkae096
Giulia Maneri, Camilla Nero, Luciano Giacò, Giovanni Scambia, Angelo Minucci

The majority of tumor comprehensive genomic profiling (CGP) currently does not include a matched normal control. The use of a tumor-only CGP approach needs the development of a strategy to refine germline pathogenic/likely pathogenic variants (gP/LPVs) calls, so as to limit the performance of unnecessary germline reflex tests and instead successfully identify patients who are carriers of likely gP/LPVs. Guidelines have been developed for the identification of gP/LPVs in BRCA1/2 genes on the basis of tumor-only CGP results and for the evaluation of the appropriateness of performing germline reflex BRCA1/2 testing. In this study, an algorithm to assist decision-making for germline reflex testing of BRCA1/2 variants following tumor-only CGP is proposed.

目前,大多数肿瘤综合基因组图谱(CGP)都不包括匹配的正常对照。使用纯肿瘤 CGP 方法需要开发一种策略来完善种系致病/可能致病变异(gP/LPVs)的调用,从而限制不必要的种系反射测试,转而成功鉴定可能是 gP/LPVs 携带者的患者。目前已制定了指南,用于根据纯肿瘤 CGP 结果鉴定 BRCA1/2 基因中的 gP/LPVs 以及评估进行生殖系反射 BRCA1/2 检测是否合适。在本研究中,提出了一种算法,用于辅助在纯肿瘤 CGP 之后对 BRCA1/2 基因变异进行种系反射检测的决策。
{"title":"Germline reflex BRCA1/2 testing following tumor-only comprehensive genomic profiling: why, when, and how.","authors":"Giulia Maneri, Camilla Nero, Luciano Giacò, Giovanni Scambia, Angelo Minucci","doi":"10.1093/jncics/pkae096","DOIUrl":"10.1093/jncics/pkae096","url":null,"abstract":"<p><p>The majority of tumor comprehensive genomic profiling (CGP) currently does not include a matched normal control. The use of a tumor-only CGP approach needs the development of a strategy to refine germline pathogenic/likely pathogenic variants (gP/LPVs) calls, so as to limit the performance of unnecessary germline reflex tests and instead successfully identify patients who are carriers of likely gP/LPVs. Guidelines have been developed for the identification of gP/LPVs in BRCA1/2 genes on the basis of tumor-only CGP results and for the evaluation of the appropriateness of performing germline reflex BRCA1/2 testing. In this study, an algorithm to assist decision-making for germline reflex testing of BRCA1/2 variants following tumor-only CGP is proposed.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Structural racism and inequity in cancer clinical trial participation: time for solutions. 癌症临床试验参与中的结构性种族主义和不公平现象:是时候找到解决方案了。
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-09-02 DOI: 10.1093/jncics/pkae089
Abhijit Pal, Rayan Saleh Moussa, Ben Smith, Bernadette Brady, Deme Karikios, Frances Boyle, Wei Chua
{"title":"Structural racism and inequity in cancer clinical trial participation: time for solutions.","authors":"Abhijit Pal, Rayan Saleh Moussa, Ben Smith, Bernadette Brady, Deme Karikios, Frances Boyle, Wei Chua","doi":"10.1093/jncics/pkae089","DOIUrl":"https://doi.org/10.1093/jncics/pkae089","url":null,"abstract":"","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11495864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival prediction in sigmoid colon cancer patients with liver metastasis: a prospective cohort study. 肝转移乙状结肠癌患者的生存预测:一项前瞻性队列研究。
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-09-02 DOI: 10.1093/jncics/pkae080
Shuai Shao, Dan Tian, Mingyang Li, Shanshan Wu, Dong Zhang

Background: Sigmoid colon cancer is a common type of colorectal cancer, frequently leading to liver metastasis. Predicting cause-specific survival and overall survival in patients with sigmoid colon cancer metastasis to liver is challenging because of the lack of suitable models.

Methods: Patients with sigmoid colon cancer metastasis to liver (2010-2017) in the Surveillance, Epidemiology, and End Results (SEER) Program were recruited. Patients were split into training and validation groups (7:3). Prognostic factors were identified using competing risk and Cox proportional hazards models, and nomograms for cause-specific survival and overall survival were developed. Model performance was evaluated with the concordance index and calibration curves, with a 2-sided P value less than .05 considered statistically significant.

Results: A total of 4981 sigmoid colon cancer with liver metastasis patients were included, with a median follow-up of 20 months (interquartile range [IQR] = 9-33 months). During follow-up, 72.25% of patients died (68.44% from sigmoid colon cancer, 3.81% from other causes). Age, race, grade, T stage, N stage, surgery, chemotherapy, carcinoembryonic antigen, tumor deposits, lung metastasis, and tumor size were prognostic factors for cause-specific survival and overall survival. The models demonstrated good discrimination and calibration performance, with C index values of 0.79 (95% confidence interval [CI] = 0.78 to 0.80) for cause-specific survival and 0.74 (95% CI = 0.73 to 0.75) for overall survival. A web-based application for real-time cause-specific survival predictions was created, accessible at https://shuaishao.shinyapps.io/SCCLM/.

Conclusion: Prognostic factors for sigmoid colon cancer with liver metastasis patients were identified based on the SEER database, and nomograms for cause-specific survival and overall survival showed good performance. A web-based application was developed to predict sigmoid colon cancer with liver metastasis-specific survival, aiding in survival risk stratification.

目的:乙状结肠癌(SCC)是一种常见的结直肠癌,经常导致肝转移。由于缺乏合适的模型,预测伴有肝转移的SCC患者的病因特异性生存率(CSS)和总生存率(OS)具有挑战性:招募了监测、流行病学和最终结果(SEER)计划中的SCCLM患者数据(2010-2017年)。患者被分为训练组和验证组(7:3)。使用竞争风险模型和 Cox 比例危险模型确定预后因素,并绘制 CSS 和 OS 的提名图。利用一致性指数和校准曲线评估模型的性能,采用双侧 p 结果:共纳入 4981 例 SCCLM 患者,中位随访时间为 20 个月(IQR:9-33 个月)。随访期间,72.25%的患者死亡(68.44%死于SCC,3.81%死于其他原因)。年龄、种族、分级、T期、N期、手术、化疗、CEA、肿瘤沉积物、肺转移和肿瘤大小是CSS和OS的预后因素。这些模型具有良好的区分度和校准性能,CSS的C指数值为0.79(95% CI:0.78-0.80),OS的C指数值为0.74(95% CI:0.73-0.75)。我们创建了一个用于实时预测 CSS 的网络应用程序,可通过 https://shuaishao.shinyapps.io/SCCLM/.Conclusion 访问:根据SEER数据库确定了SCCLM患者的预后因素,CSS和OS的提名图表现良好。开发了一款网络应用程序,用于预测SCCLM特异性生存率,帮助进行生存风险分层。
{"title":"Survival prediction in sigmoid colon cancer patients with liver metastasis: a prospective cohort study.","authors":"Shuai Shao, Dan Tian, Mingyang Li, Shanshan Wu, Dong Zhang","doi":"10.1093/jncics/pkae080","DOIUrl":"10.1093/jncics/pkae080","url":null,"abstract":"<p><strong>Background: </strong>Sigmoid colon cancer is a common type of colorectal cancer, frequently leading to liver metastasis. Predicting cause-specific survival and overall survival in patients with sigmoid colon cancer metastasis to liver is challenging because of the lack of suitable models.</p><p><strong>Methods: </strong>Patients with sigmoid colon cancer metastasis to liver (2010-2017) in the Surveillance, Epidemiology, and End Results (SEER) Program were recruited. Patients were split into training and validation groups (7:3). Prognostic factors were identified using competing risk and Cox proportional hazards models, and nomograms for cause-specific survival and overall survival were developed. Model performance was evaluated with the concordance index and calibration curves, with a 2-sided P value less than .05 considered statistically significant.</p><p><strong>Results: </strong>A total of 4981 sigmoid colon cancer with liver metastasis patients were included, with a median follow-up of 20 months (interquartile range [IQR] = 9-33 months). During follow-up, 72.25% of patients died (68.44% from sigmoid colon cancer, 3.81% from other causes). Age, race, grade, T stage, N stage, surgery, chemotherapy, carcinoembryonic antigen, tumor deposits, lung metastasis, and tumor size were prognostic factors for cause-specific survival and overall survival. The models demonstrated good discrimination and calibration performance, with C index values of 0.79 (95% confidence interval [CI] = 0.78 to 0.80) for cause-specific survival and 0.74 (95% CI = 0.73 to 0.75) for overall survival. A web-based application for real-time cause-specific survival predictions was created, accessible at https://shuaishao.shinyapps.io/SCCLM/.</p><p><strong>Conclusion: </strong>Prognostic factors for sigmoid colon cancer with liver metastasis patients were identified based on the SEER database, and nomograms for cause-specific survival and overall survival showed good performance. A web-based application was developed to predict sigmoid colon cancer with liver metastasis-specific survival, aiding in survival risk stratification.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11476935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The silent struggle: anxiety in men with prostate cancer. 无声的挣扎:男性前列腺癌患者的焦虑。
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-09-02 DOI: 10.1093/jncics/pkae094
Zhiyu Qian, Stephan M Korn, Quoc-Dien Trinh
{"title":"The silent struggle: anxiety in men with prostate cancer.","authors":"Zhiyu Qian, Stephan M Korn, Quoc-Dien Trinh","doi":"10.1093/jncics/pkae094","DOIUrl":"https://doi.org/10.1093/jncics/pkae094","url":null,"abstract":"","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The intersection of travel burdens and financial hardship in cancer care: a scoping review. 癌症护理中旅行负担与经济困难的交集:范围审查。
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-09-02 DOI: 10.1093/jncics/pkae093
Arrianna Marie Planey, Lisa P Spees, Caitlin B Biddell, Austin Waters, Emily P Jones, Hillary K Hecht, Donald Rosenstein, Stephanie B Wheeler

Background: In addition to greater delays in cancer screening and greater financial hardship, rural-dwelling cancer patients experience greater costs associated with accessing cancer care, including higher cumulative travel costs. This study aimed to identify and synthesize peer-reviewed research on the cumulative and overlapping costs associated with care access and utilization.

Methods: A scoping review was conducted to identify relevant studies published after 1995 by searching 5 electronic databases: PubMed, Scopus, Cumulative Index of Nursing and Allied Health Literature (CINAHL), PsycInfo, and Healthcare Administration. Eligibility was determined using the PEO (Population, Exposure, and Outcomes) method, with clearly defined populations (cancer patients), exposures (financial hardship, toxicity, or distress; travel-related burdens), and outcomes (treatment access, treatment outcomes, health-related quality of life, and survival/mortality). Study characteristics, methods, and findings were extracted and summarized.

Results: Database searches yielded 6439 results, of which 3366 were unique citations. Of those, 141 were eligible for full-text review, and 98 studies at the intersection of cancer-related travel burdens and financial hardship were included. Five themes emerged as we extracted from the full texts of the included articles: 1) Cancer treatment choices, 2) Receipt of guideline-concordant care, 3) Cancer treatment outcomes, 4) Health-related quality of life, and 5) Propensity to participate in clinical trials.

Conclusions: This scoping review identifies and summarizes available research at the intersection of cancer care-related travel burdens and financial hardship. This review will inform the development of future interventions aimed at reducing the negative effects of cancer-care related costs on patient outcomes and quality of life.

背景:除了癌症筛查的更多延误和更大的经济困难之外,居住在农村的癌症患者在接受癌症治疗时还需要支付更多的相关费用,包括更高的累积旅行费用。本研究旨在确定和综合经同行评审的、与获得和利用医疗服务相关的累积和重叠成本的研究:通过搜索五个电子数据库,对 1995 年之后发表的相关研究进行了范围界定:PubMed、Scopus、Cumulative Index of Nursing and Allied Health Literature (CINAHL)、PsycInfo 和 Healthcare Administration。采用 PEO(人群、暴露和结果)方法确定研究资格,明确界定人群(癌症患者)、暴露(经济困难、毒性或痛苦;与旅行相关的负担)和结果(治疗机会、治疗结果、与健康相关的生活质量和存活率/死亡率)。对研究特点、方法和结果进行了提取和总结:结果:通过数据库检索获得了 6,439 条结果,其中 3,366 条为唯一引用。其中 141 篇符合全文审阅条件,98 篇与癌症相关的旅行负担和经济困难相关的研究被纳入其中。我们从收录文章的全文中提取出了五 (5) 个主题:(1) 癌症治疗选择;(2) 接受与指南一致的护理;(3) 癌症治疗结果;(4) 与健康相关的生活质量;(5) 参与临床试验的倾向:本范围界定综述确定并总结了与癌症护理相关的旅行负担和经济困难交叉点的现有研究。该综述将为今后制定旨在减少癌症治疗相关费用对患者预后和生活质量的负面影响的干预措施提供参考。
{"title":"The intersection of travel burdens and financial hardship in cancer care: a scoping review.","authors":"Arrianna Marie Planey, Lisa P Spees, Caitlin B Biddell, Austin Waters, Emily P Jones, Hillary K Hecht, Donald Rosenstein, Stephanie B Wheeler","doi":"10.1093/jncics/pkae093","DOIUrl":"10.1093/jncics/pkae093","url":null,"abstract":"<p><strong>Background: </strong>In addition to greater delays in cancer screening and greater financial hardship, rural-dwelling cancer patients experience greater costs associated with accessing cancer care, including higher cumulative travel costs. This study aimed to identify and synthesize peer-reviewed research on the cumulative and overlapping costs associated with care access and utilization.</p><p><strong>Methods: </strong>A scoping review was conducted to identify relevant studies published after 1995 by searching 5 electronic databases: PubMed, Scopus, Cumulative Index of Nursing and Allied Health Literature (CINAHL), PsycInfo, and Healthcare Administration. Eligibility was determined using the PEO (Population, Exposure, and Outcomes) method, with clearly defined populations (cancer patients), exposures (financial hardship, toxicity, or distress; travel-related burdens), and outcomes (treatment access, treatment outcomes, health-related quality of life, and survival/mortality). Study characteristics, methods, and findings were extracted and summarized.</p><p><strong>Results: </strong>Database searches yielded 6439 results, of which 3366 were unique citations. Of those, 141 were eligible for full-text review, and 98 studies at the intersection of cancer-related travel burdens and financial hardship were included. Five themes emerged as we extracted from the full texts of the included articles: 1) Cancer treatment choices, 2) Receipt of guideline-concordant care, 3) Cancer treatment outcomes, 4) Health-related quality of life, and 5) Propensity to participate in clinical trials.</p><p><strong>Conclusions: </strong>This scoping review identifies and summarizes available research at the intersection of cancer care-related travel burdens and financial hardship. This review will inform the development of future interventions aimed at reducing the negative effects of cancer-care related costs on patient outcomes and quality of life.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11519048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse social determinants of health elevate uncontrolled hypertension risk: a cardio-oncology prospective cohort study. 不利的社会健康决定因素会增加未控制的高血压风险:一项心脏病-肿瘤学前瞻性队列研究。
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-09-02 DOI: 10.1093/jncics/pkae064
Priyanshu Nain, Nickolas Stabellini, Omar M Makram, Johnathan Rast, Sandeep Yerraguntla, Gaurav Gopu, Aditya Bhave, Lakshya Seth, Vraj Patel, Stephanie Jiang, Sarah Malik, Ahmed Shetewi, Alberto J Montero, Jennifer Cullen, Neeraj Agarwal, Xiaoling Wang, Bonnie Ky, Lauren A Baldassarre, Neal L Weintraub, Ryan A Harris, Avirup Guha

The role of social determinants of health (SDOH) in controlling hypertension (HTN) in cancer patients is unknown. We hypothesize that high SDOH scores correlate with uncontrolled HTN in hypertensive cancer patients. In our prospective study, patients completed the Protocol for Responding to & Assessing Patients' Assets, Risks & Experiences questionnaire. After integrating home and clinic blood pressure readings, uncontrolled HTN was defined as systolic blood pressure greater than or equal to 140 mm Hg and/or diastolic blood pressure greater than or equal to 90 mm Hg. Using Cox regression, we analyzed the impact of SDOH on HTN control, adjusting for relevant factors. The study involved 318 participants (median age 66.4, median follow-up 166 days, SDOH score 6.5 ± 3.2), with stress, educational insecurity, and social isolation as prevalent adverse SDOH. High SDOH scores led to 77% increased risk of uncontrolled HTN (adjusted hazards ratio = 1.77; 95% confidence interval = 1.10 to 2.83, P = .018). Urban residents with high SDOH scores were at an even greater risk. Identifying SDOH and mitigating underlying factors may help control HTN, the most typical disease process treated in all cardio-oncology clinics.

健康的社会决定因素(SDOH)在控制癌症患者高血压(HTN)方面的作用尚不清楚。我们假设,SDOH 分数高与高血压癌症患者的高血压未得到控制有关。在我们的前瞻性研究中,患者填写了 PRAPARE 问卷。综合家庭和诊所血压读数后,未控制的高血压被定义为 SBP ≥ 140 mmHg 和/或 DBP ≥ 90 mmHg。我们使用 Cox 回归分析了 SDOH 对高血压控制的影响,并对相关因素进行了调整。研究涉及 318 名参与者(中位年龄 66.4 岁,中位随访 166 天,SDOH 评分 6.5 ± 3.2),压力、教育不安全和社会隔离是普遍存在的不良 SDOH。SDOH得分高会使高血压得不到控制的风险增加77%(aHR 1.77;95% CI 1.10-2.83,p = .018)。SDOH得分高的城市居民面临的风险更大。识别 SDOH 并减轻潜在因素可能有助于控制高血压,这是所有心脏病肿瘤诊所治疗的最典型的疾病过程。
{"title":"Adverse social determinants of health elevate uncontrolled hypertension risk: a cardio-oncology prospective cohort study.","authors":"Priyanshu Nain, Nickolas Stabellini, Omar M Makram, Johnathan Rast, Sandeep Yerraguntla, Gaurav Gopu, Aditya Bhave, Lakshya Seth, Vraj Patel, Stephanie Jiang, Sarah Malik, Ahmed Shetewi, Alberto J Montero, Jennifer Cullen, Neeraj Agarwal, Xiaoling Wang, Bonnie Ky, Lauren A Baldassarre, Neal L Weintraub, Ryan A Harris, Avirup Guha","doi":"10.1093/jncics/pkae064","DOIUrl":"10.1093/jncics/pkae064","url":null,"abstract":"<p><p>The role of social determinants of health (SDOH) in controlling hypertension (HTN) in cancer patients is unknown. We hypothesize that high SDOH scores correlate with uncontrolled HTN in hypertensive cancer patients. In our prospective study, patients completed the Protocol for Responding to & Assessing Patients' Assets, Risks & Experiences questionnaire. After integrating home and clinic blood pressure readings, uncontrolled HTN was defined as systolic blood pressure greater than or equal to 140 mm Hg and/or diastolic blood pressure greater than or equal to 90 mm Hg. Using Cox regression, we analyzed the impact of SDOH on HTN control, adjusting for relevant factors. The study involved 318 participants (median age 66.4, median follow-up 166 days, SDOH score 6.5 ± 3.2), with stress, educational insecurity, and social isolation as prevalent adverse SDOH. High SDOH scores led to 77% increased risk of uncontrolled HTN (adjusted hazards ratio = 1.77; 95% confidence interval = 1.10 to 2.83, P = .018). Urban residents with high SDOH scores were at an even greater risk. Identifying SDOH and mitigating underlying factors may help control HTN, the most typical disease process treated in all cardio-oncology clinics.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cognitive function in long-term testicular cancer survivors: impact of modifiable factors. 睾丸癌长期存活者的认知功能:可改变因素的影响
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-09-02 DOI: 10.1093/jncics/pkae068
Paul C Dinh, Patrick O Monahan, Chunkit Fung, Howard D Sesso, Darren R Feldman, David J Vaughn, Robert J Hamilton, Robert Huddart, Neil E Martin, Christian Kollmannsberger, Sandra Althouse, Lawrence H Einhorn, Robert Frisina, James C Root, Tim A Ahles, Lois B Travis

No study has comprehensively examined associated factors (adverse health outcomes, health behaviors, and demographics) affecting cognitive function in long-term testicular cancer survivors (TC survivors). TC survivors given cisplatin-based chemotherapy completed comprehensive, validated surveys, including those that assessed cognition. Medical record abstraction provided cancer and treatment history. Multivariable logistic regression examined relationships between potential associated factors and cognitive impairment. Among 678 TC survivors (median age = 46; interquartile range [IQR] = 38-54); median time since chemotherapy = 10.9 years, IQR = 7.9-15.9), 13.7% reported cognitive dysfunction. Hearing loss (odds ratio [OR] = 2.02; P = .040), neuropathic pain (OR = 2.06; P = .028), fatigue (OR = 6.11; P < .001), and anxiety/depression (OR = 1.96; P = .029) were associated with cognitive impairment in multivariable analyses. Being on disability (OR = 9.57; P = .002) or retired (OR = 3.64; P = .029) were also associated with cognitive decline. Factors associated with impaired cognition identify TC survivors requiring closer monitoring, counseling, and focused interventions. Hearing loss, neuropathic pain, fatigue, and anxiety/depression constitute potential targets for prevention or reduction of cognitive impairment in long-term TC survivors.

目前还没有研究对影响睾丸癌长期存活者(TC-幸存者)认知功能的相关因素(不良健康后果、健康行为和人口统计学特征)进行全面研究。接受过顺铂化疗的睾丸癌幸存者完成了经过验证的综合调查,其中包括评估认知功能的调查。病历摘要提供了癌症和治疗史。多变量逻辑回归检验了潜在相关因素与认知障碍之间的关系。在 678 名 TC 幸存者[中位年龄:46(IQR:38,54);化疗后的中位时间:10.9 年(IQR = 7.9,15.9)]中,13.7% 报告了认知功能障碍。听力损失(OR = 2.02;P = .040)、神经病理性疼痛(OR = 2.06;P = .028)、疲劳(OR = 6.11;P
{"title":"Cognitive function in long-term testicular cancer survivors: impact of modifiable factors.","authors":"Paul C Dinh, Patrick O Monahan, Chunkit Fung, Howard D Sesso, Darren R Feldman, David J Vaughn, Robert J Hamilton, Robert Huddart, Neil E Martin, Christian Kollmannsberger, Sandra Althouse, Lawrence H Einhorn, Robert Frisina, James C Root, Tim A Ahles, Lois B Travis","doi":"10.1093/jncics/pkae068","DOIUrl":"10.1093/jncics/pkae068","url":null,"abstract":"<p><p>No study has comprehensively examined associated factors (adverse health outcomes, health behaviors, and demographics) affecting cognitive function in long-term testicular cancer survivors (TC survivors). TC survivors given cisplatin-based chemotherapy completed comprehensive, validated surveys, including those that assessed cognition. Medical record abstraction provided cancer and treatment history. Multivariable logistic regression examined relationships between potential associated factors and cognitive impairment. Among 678 TC survivors (median age = 46; interquartile range [IQR] = 38-54); median time since chemotherapy = 10.9 years, IQR = 7.9-15.9), 13.7% reported cognitive dysfunction. Hearing loss (odds ratio [OR] = 2.02; P = .040), neuropathic pain (OR = 2.06; P = .028), fatigue (OR = 6.11; P < .001), and anxiety/depression (OR = 1.96; P = .029) were associated with cognitive impairment in multivariable analyses. Being on disability (OR = 9.57; P = .002) or retired (OR = 3.64; P = .029) were also associated with cognitive decline. Factors associated with impaired cognition identify TC survivors requiring closer monitoring, counseling, and focused interventions. Hearing loss, neuropathic pain, fatigue, and anxiety/depression constitute potential targets for prevention or reduction of cognitive impairment in long-term TC survivors.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JNCI Cancer Spectrum
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1